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Introduction
Mammalian myocardium contains large quantities of neuropeptide Y (NPY) (Onuoha et al., 1999) , mainly co-localised with noradrenaline in perivascular sympathetic neurons innervating cardiac tissue (Franco-Cereceda et al., 1985; Allen et al., 1986) . NPY has been implicated in left ventricular hypertrophy (LVH), an initial compensatory response of the heart to pressure overload precipitated by hypertension (Agabiti-Rosei and Muiesan, 2001 ) since increased plasma levels of the peptide are found in hypertension, myocardial infarction and heart failure (Maisel et al., 1989) , and correlate with severity of LVH (Hulting et al., 1990) .
NPY can both decrease and increase the contractile response of electrically-stimulated rat ventricular cardiomyocytes (Piper et al., 1989; Millar et al., 1991) . The negative effect, observed in isoproterenol-treated cells, is due primarily to stimulation of the transient outward current (I to ) and mediated through an inhibitory G protein / adenylate cyclase pathway (Kassis et al., 1987; Piper et al., 1989; Millar et al., 1991) . Use of the selective Y 2 receptor agonists, PYY 3-36 and NPY 13-36 inferred Y 2 receptor involvement (McDermott et al., 1997) , but the finding that long Cterminal fragments of both PYY and NPY also exhibit high affinity for the Y 5 receptor subtype (Hu et al., 1996) emphasizes the need for clarification of receptor subtypes involved in NPYstimulated cardiomyocyte contraction. NPY alone does not influence the basal level of contraction of cardiomyocytes, but in the presence of 4-aminopyridine, which inhibits selectively I to in these cells, a positive response to NPY is unmasked (Millar et al., 1991) . This has been observed also in chicken cardiomyocytes in the absence of rectifier current blockade (Jacques et al., 2000) and both effects are attributed to influx of Ca 2+ via L-type channels and mediated through Y 1 receptor stimulation. Furthermore, Y 1 receptors are also coupled to mobilisation of intracellular calcium stores in cardiomyocytes by a phospholipase C-dependent mechanism (Heredia et al., 2005) .
This article has not been copyedited and formatted. The final version may differ from this version. (Hanna and Khairallah, 1986) . The release of NPY from the cardiac sympathetic innervation would also be expected to be enhanced during the pathogenesis of hypertension-induced myocardial hypertrophy, indeed the plasma concentration (Zukowskagrojec et al., 1993; Bohm et al., 1995) and platelet content (Ogawa et al., 1992; Zukowskagrojec et al., 1993; Chen and Han, 1995) of NPY are increased, and alterations in NPY-mediated myocardial contractile responses may be anticipated, since receptors for the peptide couple to signal transduction processes known to be altered in hypertrophied cardiomyocytes (Kawaguchi et al, 1992; Bohm et al, 1994; Cerbai et al., 1994; Xiao and McArdle, 1994; Yokoshiki et al, 1997) .
The spontaneously hypertensive rat (SHR) is a useful model of pressure overload, (Okamoto and Aoki, 1963; Pfeffer et al., 1976) in which hypertension, evident at ≥7 weeks of age, is followed by development of ventricular hypertrophy; a 'hypertrophic window' at 12-20 weeks, which encompasses baseline and developmental characteristics at cardiomyocyte level, has been identified (Bell et al., 2004) . Furthermore, the Y 5 receptor becomes coupled transiently to the stimulation of protein synthesis by NPY during the active phase of development of ventricular cell hypertrophy in the SHR although receptor number is unaltered (Bell et al., 2002 Isolation and culture of cardiomyocytes: After deep anaesthesia of the rat using isoflurane (Abbott Laboratories, Kent, UK), the heart was excised quickly and placed in ice-cold 0.9% (w/v) NaCl. The heart was cannulated through the ascending aorta and ventricular cardiomyocytes were isolated by the Langendorff retrograde perfusion method described previously (Bell et al., 2002) . After purification, cells were suspended at a concentration of1.5 x 10 5 viable cardiomyocytes.ml -1 in CCT medium.
Analysis of contraction function:
An aliquot of myocyte suspension (≈150 µl) was placed in a transparent recording chamber mounted on an inverted phase-contrast microscope (Axiovert IM35, Carl Zeiss, Germany), and allowed to settle for 10 min before being bathed with oxygenated (95% O 2 , 5% CO 2 ) Krebs-Henseleit buffer. Cells were field-stimulated at 0. edge detection equipment and the procedure used in the measurement of contraction amplitude were those described by Kelso et al. (2000) .
Real-Time PCR: Total cellular RNA was isolated using acid guanidinium thiocyanate-phenolchloroform extraction and alterations in mRNA expression determined by RT-PCR and expressed relative to GAPDH mRNA. Reported sequences for each gene (Table 1) were used to design on Primer Express software (PE Applied Biosystems), rat specific primers adapted to RT-PCR conditions, which were synthesized by Invitrogen. RT-PCR and subsequent analysis were performed as described previously (Zhao et al., 2006) .
Immunodetection and quantification of membrane protein: membranes were prepared from viable left ventricular cardiomyocytes as described previously (Zhao et al., 2006 
Results
Control experiments for the effect of NPY and associated compounds on contractile function
The following agonists had no effect per se with Ca 2+ (10 -3 mol/L) on contractile amplitude with increasing age of SHRs, the concentration used in 16 and 20 week old rats was 3 x 10 -10 mol/L, but was 3 x 10 -9 mol/L in 12 week old SHRs and all WKY rats.
Receptor subtype-mediated effects on electrically-stimulated contraction of rat cardiomyocytes
Data obtained in our laboratory establishing the temporal development of hypertension and cardiomyocyte hypertrophy in SHRs during the period 12-20 weeks employed in the contraction experiments below have been published previously (Bell et al., 2004) . which, when used alone, had increased contraction amplitude in SHR and WKY rat cardiomyocytes, had no effect on amplitude of contraction (Figure 3b ).
Temporal and concentration-dependence of the negative contraction response to PYY 3-36 alone:
PYY 3-36 (10 -12 to 3x10 -9 mol/L) elicited a concentration-dependent, negative contraction effect in cardiomyocytes from SHRs and WKY rats of all ages (Figure 4) . Maximum responses to PYY did not differ significantly between SHR and WKY rats at any age. The potency of PYY 3-36 was similar in cardiomyocytes from 12 week old rats of each strain, in the region of 3x10 -10 mol/L, and in WKY rat cardiomyocytes was unchanged with progression of age, whereas potency increased in SHRs, becoming significantly elevated (x400) in cardiomyocytes from 20 compared to 12 week old rats. Figure 1b . NPY at 10 -12 to 3x10 -9 mol/L reduced the positive contraction effect of isoproterenol in cardiomyocytes from both rat strains at all ages ( Figure 5 a, b) . In cardiomyocytes from 12 week old rats, the potency of NPY was in the region of 100 pmol/L and was unaltered with increasing age in WKY rats, but increased (60-fold) in SHRs, being significant in 20 compared to 12 week old rats. When cardiomyocytes from age-matched WKY rats and SHRs were compared, the potency of NPY was significantly increased, 175-fold, only at 20 weeks.
Temporal and concentration-dependence of the negative contraction responses to PYY 3-36 in isoproterenol-stimulated cells:
Comparison of the effects of PYY 3-36 and NPY to attenuate isoproterenol-stimulated contraction amplitude showed that, in all cases, the potencies of both peptides were similar. As such, the potency of PYY 3-36 to decrease contraction amplitude was unchanged in WKY rat cardiomyocytes but enhanced in cardiomyocytes obtained from SHRs at 20 weeks of age (145-fold vs. age-matched controls). PYY 3-36 was equally potent in attenuating isoproterenol-stimulated contraction amplitude ( Figure 5 ) and in eliciting decreased contraction amplitude under elevated extracellular Ca 2+ conditions (Figure 4) . BIIE246, applied at a concentration (10 -7 mol/L) at which it has high affinity for the Y 2 receptor subtype but virtually no affinity for the Y 1 , Y 4 and Y 5 receptor subtypes (Doods et al., 1999) abolished the maximal attenuation of isoproterenol-stimulated contraction amplitude elicited by NPY ) at all This article has not been copyedited and formatted. The final version may differ from this version. (Grandt et al., 1996) , it has now been shown that long C-terminal fragments of either NPY or PYY also have high potency at the Y 5 receptor (Hu et al., 1996) . However, the latter does not appear to be involved in mediating the negative contraction effects of NPY (or (Millar et al., 1988; Hu et al., 1996) . in WKY rat myocytes is less than the in vivo plasma concentration of NPY (Ogawa et al., 1989) .
Therefore, the Y 2 receptor-mediated negative contraction effect may also be a redundant mechanism in normotensive animals. However, the potency of both peptides to elicit this negative effect was up-regulated in cardiomyocytes from 20 week old SHRs to a level at which the observed circulatory concentration of NPY would be expected to elicit a maximal negative effect. Again this is consistent with the hypothesis that in hypertensive disease, peptidic regulation of the myocardium is enhanced. stress. Prolonged activation of sympathetic drive however would be expected to increase myocardial oxygen demand and energy expenditure of the hypertrophied myocardium, thereby contributing to cardiomyocyte ischemia and eventually cell death due to apoptosis or necrosis, resulting in impaired contractility of the residual myocardium and reduced ability to sustain the increased load since adult cardiomyocytes have only limited potential for self-renewal (Anversa et al., 2006) . Enhancement of the negative contraction effect of NPY during early compensated hypertensive LVH could therefore represent a protective measure to help to counter the excessive shortening and energy expenditure of cardiomyocytes in response to norepinephrine. However, impaired intrinsic myocardial contractility has also been observed in patients with prolonged hypertension despite fully compensated ventricular hypertrophy, normal wall stress and apparently normal pump function (Aoyagi et al., 1993) . The possibility should be considered that chronic enhancement of the negative contraction effects of NPY could instead represent a pathophysiological phenomenon, such that sustained depression of contractility mediated via Y 2 receptor stimulation may exacerbate progressive mechanical dysfunction and impair ventricular emptying during systole and ultimately accelerate transition to overt failure. calcium stores is enhanced in SHR myocardium (Kawaguchi et al, 1992; . Since Y 1 receptors are known to couple to mobilisation of intracellular calcium stores in cardiomyocytes by a phospholipase C-dependent mechanism (Heredia et al., 2005) , enhanced activity downstream of the receptor-involvement could compensate for, or alternatively may contribute to recruitment of processes responsible for the modest reduction in Y 1 receptor number. (2) Expression of G i -α subunit protein is also enhanced and G i − mediated inhibition of adenylate cyclase augmented (Bohm et al, 1994) implying enhanced activity downstream of the Y 2 receptor. Again, this could compensate for, or alternatively may contribute to the regulation of processes responsible for the modest reduction in Y 2 receptor number. However, I to current is blunted (Cerbai et al., 1994; Yokoshiki et al, 1997) while conversely L-type calcium channel current is enhanced (Xiao and McArdle, 1994) , (6.7 ± 2.6) x 10 -10 , (7.9 ± 2.6) x 10 , (7.5 ± 4.5) x 10 -13 * † ‡ in SHRs, respectively. *p<0.05 vs. strain-matched 12 week old rats, † p<0.05 vs. strain-matched 16 week old rats, ‡ p<0.05 vs. age-matched WKY rats. 
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